Here's Why Galectin Therapeutics (GALT) Is Poised for a Turnaround After Losing -31.83% in 4 Weeks

Zacks Dec 9 21:40

Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings

Seeking AlphaNov 30 01:00

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

BenzingaNov 18 21:01

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More

Seeking AlphaNov 18 13:09

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11

Futu NewsNov 15 20:33 · Ratings

Optimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost Prospects

TipRanksNov 15 19:35 · Ratings